Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 12/20 | 0.55 |
| ▸ | SLC5A2 | P31639 | 12/20 | 0.55 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139493 | 0.91 | SLC5A1 (0.44) | SLC5A1SLC5A2SSTR1SSTR2SSTR4 | |
| SCHEMBL20139439 | 0.90 | SLC5A1 (0.58) | SLC5A1SLC5A2SSTR1SSTR2SSTR4 | |
| SCHEMBL20139436 | 0.90 | SLC5A2 (0.55) | SLC5A1SLC5A2SSTR1SSTR2SSTR4 | |
| SCHEMBL20140270 | 0.89 | SLC5A1 (0.49) | SLC5A1SLC5A2SSTR1SSTR2SSTR4 | |
| SCHEMBL20139407 | 0.88 | SLC5A1 (0.46) | SLC5A1SLC5A2TACR2PTPN1CDC25B | |
| SCHEMBL20140122 | 0.85 | SLC5A1 (0.42) | SLC5A1SLC5A2SSTR1SSTR2SSTR4 | |
| SCHEMBL20139702 | 0.85 | SLC5A2 (0.53) | SLC5A1SLC5A2SSTR1SSTR2SSTR4 | |
| SCHEMBL20139474 | 0.84 | SLC5A1 (0.53) | SLC5A1SLC5A2SSTR1SSTR2SSTR4 | |
| SCHEMBL20139417 | 0.82 | SLC5A1 (0.43) | SLC5A1SLC5A2PTPN1CDC25B | |
| SCHEMBL20139434 | 0.81 | SLC5A1 (0.51) | SLC5A1SLC5A2SSTR1SSTR2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | SLC5A1 2/4885SLC5A2 1/4885SSTR1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.